TherapeuticsMD (TXMD) Provides Update on Third Quarter Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
TherapeuticsMD Provides Update on Third Quarter Progress
September 25, 2020 9:02 AM EDT-Company believes industry prescription tracking databases are not accurately tracking ANNOVERA®-
-Underlying retail and wholesale demand for ANNOVERA is strong and growing-
-Company experiencing record retail and wholesale growth for ANNOVERA-
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative womens healthcare company, today announced that the Company is on track to meet or exceed third quarter 2020 total net revenue consensus of $15.1 million. For the Companys ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) product, the Company has seen... More
